The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation

Jonathan D. Tward; Lauren Lenz; Darl D. Flake; Saradha Rajamani; Paul Yonover; Carl A. Olsson; Deepak Kapoor; C.A. Mantz; Stanley L. Liauw; Tatjana Antic; Michael D. Fabrizio; Daniel Salzstein; Neal D. Shore; Dan Albertson; Jonathan Henderson; Steve P. Lee; Hiram A. Gay; Jeff M. Michalski; Arthur Hung; David Raben; Isla P. Garraway; Michael Lewis; Paul L. Nguyen; David T. Marshall; Michael K. Brawer; Steven Stone; Todd Cohen

doi:10.1016/j.ijrobp.2021.09.034

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The CCR score accurately and precisely prognosticates metastasis and adds clinically actionable information relative to guideline-recommended therapies based on NCCN risk in men undergoing dose-escalated RT with or without ADT. For men with scores below the multimodality threshold, adding ADT may not significantly reduce their 10-year risk of metastasis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tward et al. (2021) studied this question.

synapsesocial.com/papers/69dbdb1150e1971baba3d166 https://doi.org/10.1016/j.ijrobp.2021.09.034

View Full Paper

Ask AI

Bookmark

Share

The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation

Ask about this paper

Abstract

Discussion

Cite This Study

The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading